Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human serum albumin (HSA) is the most abundant protein in human plasma, and its subdomain IIIA, also known as Sudlow's Site II, is a principal binding site for various ligands (UniProt P02768). This subdomain contains a hydrophobic pocket that preferentially binds small, aromatic carboxylic acids and neutral drugs such as ibuprofen and diazepam (Ghuman et al., 2005, PMID: 16039571). Its primary biological function involves the transport and distribution of endogenous substances like fatty acids and exogenous pharmaceuticals, thereby modulating their pharmacokinetics (Fanali et al., 2012, PMID: 22235837). In clinical practice, subdomain IIIA is a critical site for drug-drug interactions, as competition for binding can increase the free fraction of drugs, potentially leading to toxicity (Sudlow et al., 1976, PMID: 1252658).
Reversible non-covalent binding of small molecules to a hydrophobic pocket, facilitating systemic transport and modulating the free fraction of drugs in plasma.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human serum albumin (subdomain IIIA) (HSA-IIIA).